Abbott Laboratories (ABT)

The 2025 TIME 100 Most Influential Companies list includes over 40 companies that investors can buy stock in.

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.

Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session.

Forever is a tricky word in the stock market, but these stocks are as safe as they come and will pay you to hold them.

Retail sentiment surged on Stocktwits, with message volume jumping 1,600% for Abbott and 750% for Dexcom.

Abbott Laboratories has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 17.8% and now trades at $133.43. This performance may have investors wondering how to approach the situation.

ABBOTT LABORATORIES (NYSE:ABT) meets key quality investing criteria with strong revenue growth, high ROIC, and solid financial health, making it a stock worth considering for long-term portfolios.

Steady growth and dividend increases over decades can make investors remarkably wealthy.

The agreement is to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with San Diego, California- based Tandem's innovative insulin delivery systems.

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

ABBOTT LABORATORIES (NYSE:ABT) shows strong technicals and a high-quality setup, making it a potential breakout candidate for traders.

As firms continue releasing financial results late into the calendar Q1 earnings season, announcements of dividend increases also continue. Some of the latest announcements are particularly notable. This is because several companies that already have high-dividend yield stocks are increasing their quarterly payments even more.

Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral.

The company said the regulatory path forward for one of its key systems is too murky to pursue.

ABBOTT LABORATORIES (NYSE:ABT) meets key quality investing criteria with strong revenue growth, high ROIC, and excellent profit quality, making it a solid long-term candidate.

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.

ABBOTT LABORATORIES (NYSE:ABT) shows strong technicals and a high-quality breakout setup, supported by institutional interest and clear support/resistance levels.

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Abbott Laboratories (NYSE:ABT) and its peers.

"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth.